Low Dose Single Agent Chemotherapy Cured a Child with Down Syndrome and Acute Myeloid Leukemia

Basil Kadhim Abdullah Al Odda, Zardasht Bakr Mohammed, Dashti Latif Muhe Alddina, Zainab Basil Kadhim Al Odda, Ghada Basil Kadhim Al Odda, Ali Omer Qadir, Rebwar Ahmed Shrif, Ghazi Ali Fakrealdeen and Khenda Muhammed Abdullah

Department of Pediatrics, Hiwa Teaching Hospital, Iraq Department of Pediatric Hematology, Hiwa Teaching Hospital, Iraq Amman University, Jordan Freshta Secondary School, Iraq Department of Pediatric Oncology, Hiwa Teaching Hospital, Iraq Department of Pediatric Hematology and Oncology, Hiwa Teaching Hospital, Iraq

^*Correspondance to: Basil Kadhim Abdullah Al Odda 

 PDF  Full Text Case Report | Open Access

Abstract:

Patient with Down syndrome (trisomy 21) have more than 10 time increasing risk Of acute leukemia with more than 1% of children with down syndrome will develop Acute Myeloid Leukemia (AML), this increase risk occur primarily in children with Down Syndrome (DS) under the age of 10 years. Among patients with DS, AML most commonly occur between 1 to 4 years old age, megakaryocytic AML (M7) which is uncommon subtype of AML mostly affecting patients with DS. We reported a patient with Down syndrome who developed AML M2 (Myeloblastic without maturation) at the age of 2 years who was treated by single agent low dose Cytarabine (Ara-C) chemotherapy because of associated cardiac comorbidity for 24 months, currently she is 4 years off chemotherapy and on complete remission.

Keywords:

Down syndrome; Trisomy 21; Acute myeloid leukemia; Low dose chemotherapy; Atrioventricular Septal Defect (AVSD)

Cite the Article:

Al Odda BKA, Mohammed ZB, Alddina DLM, Al Odda ZBK, Al Odda GBK, Qadir AO, et al. Low Dose Single Agent Chemotherapy Cured a Child with Down Syndrome and Acute Myeloid Leukemia. Clin Oncol. 2020; 5: 1748..